Quick Answer
ICU MEDICAL INC/DE reported Total Revenue of $2.23 billion for fiscal year 2025.
ICU MEDICAL INC/DE — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $2.23B -6.3% |
$2.38B +5.4% |
$2.26B -0.9% |
$2.28B +73.2% |
$1.32B +3.6% |
$1.27B +0.4% |
| Net Income | $732.0K +100.6% |
-$117.69M -296.9% |
-$29.66M +60.1% |
-$74.29M -172.0% |
$103.14M +18.7% |
$86.87M -14.0% |
| Diluted EPS | $0.03 +100.6% |
-$4.83 -292.7% |
-$1.23 +60.5% |
-$3.11 -165.6% |
$4.74 +17.9% |
$4.02 -14.3% |
| Total Assets | $4.05B -3.6% |
$4.20B -4.0% |
$4.38B -3.0% |
$4.52B +140.1% |
$1.88B +6.6% |
$1.76B +4.2% |
| Cash and Equivalents | — | $308.57M +21.1% |
$254.72M +22.0% |
$208.78M -62.2% |
$552.83M +39.6% |
$396.10M +47.4% |
| Stockholders Equity | $2.12B +8.1% |
$1.97B -7.4% |
$2.12B +1.6% |
$2.09B +29.3% |
$1.62B +7.6% |
$1.50B +9.1% |
| R&D Expense | $87.50M -1.3% |
$88.61M +3.8% |
$85.34M -8.2% |
$92.98M +95.8% |
$47.50M +10.6% |
$42.95M -11.6% |
| Operating Income | $42.83M -0.3% |
$42.96M +88.2% |
$22.82M +153.2% |
-$42.90M -134.8% |
$123.25M +25.6% |
$98.16M -8.6% |
| Gross Profit | $822.04M -0.3% |
$824.78M +11.5% |
$739.87M +6.0% |
$697.76M +42.0% |
$491.49M +6.5% |
$461.50M -2.2% |
| Shares Outstanding | 24.69M +0.7% |
24.52M +1.6% |
24.14M +0.6% |
23.99M +12.7% |
21.28M +1.1% |
21.06M +1.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $536.99M | -8.9% | -2.2% |
| Revenue (ASC 606) | September 30, 2025 | $536.99M | -8.9% | -2.2% |
| Net Income | September 30, 2025 | -$3.40M | +89.7% | -109.6% |
| Diluted EPS | September 30, 2025 | -$0.14 | +89.6% | -109.8% |
| Total Assets | September 30, 2025 | $4.10B | -4.7% | -0.1% |
| Cash and Equivalents | September 30, 2024 | $312.51M | +57.0% | +3.3% |
| Long-Term Debt | September 30, 2025 | $1.31B | -14.9% | -1.8% |
| Stockholders Equity | September 30, 2025 | $2.13B | +3.8% | +0.5% |
| R&D Expense | September 30, 2025 | $21.25M | +1.1% | -2.8% |
| Operating Income | September 30, 2025 | $13.72M | +66.6% | +29.6% |
| Gross Profit | September 30, 2025 | $200.88M | -1.9% | -3.5% |
| Shares Outstanding | September 30, 2025 | 24.69M | +0.9% | +0.0% |
- ICU MEDICAL INC/DE reported Total Revenue of $2.23 billion for fiscal year 2025.
- ICU MEDICAL INC/DE showed a decrease of -6.3% in Total Revenue compared to the prior fiscal year.
- ICU MEDICAL INC/DE reported Net Income of $732.0 thousand for fiscal year 2025.
- ICU MEDICAL INC/DE showed an increase of +100.6% in Net Income compared to the prior fiscal year.
- ICU MEDICAL INC/DE reported Diluted EPS of $0.03 per share for fiscal year 2025.
- ICU MEDICAL INC/DE showed an increase of +100.6% in Diluted EPS compared to the prior fiscal year.
- ICU MEDICAL INC/DE reported Total Assets of $4.05 billion for fiscal year 2025.
- ICU MEDICAL INC/DE showed a decrease of -3.6% in Total Assets compared to the prior fiscal year.
- ICU MEDICAL INC/DE reported Cash and Equivalents of $308.57 million for fiscal year 2024.
- ICU MEDICAL INC/DE showed an increase of +21.1% in Cash and Equivalents compared to the prior fiscal year.
- ICU MEDICAL INC/DE reported Stockholders Equity of $2.12 billion for fiscal year 2025.
- ICU MEDICAL INC/DE showed an increase of +8.1% in Stockholders Equity compared to the prior fiscal year.
- ICU MEDICAL INC/DE reported R&D Expense of $87.50 million for fiscal year 2025.
- ICU MEDICAL INC/DE showed a decrease of -1.3% in R&D Expense compared to the prior fiscal year.
- ICU MEDICAL INC/DE reported Operating Income of $42.83 million for fiscal year 2025.
- ICU MEDICAL INC/DE showed a decrease of -0.3% in Operating Income compared to the prior fiscal year.
- ICU MEDICAL INC/DE reported Gross Profit of $822.04 million for fiscal year 2025.
- ICU MEDICAL INC/DE showed a decrease of -0.3% in Gross Profit compared to the prior fiscal year.
- ICU MEDICAL INC/DE reported Shares Outstanding of 24.69 million shares for fiscal year 2025.
- ICU MEDICAL INC/DE showed an increase of +0.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: